NASDAQ:PTIX Protagenic Therapeutics (PTIX) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free PTIX Stock Alerts $1.57 +0.32 (+25.60%) (As of 03:51 PM ET) Add Compare Share Share Today's Range$1.30▼$1.8050-Day Range$0.88▼$1.8252-Week Range$0.68▼$2.32Volume71,302 shsAverage Volume10,025 shsMarket Capitalization$6.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Protagenic Therapeutics alerts: Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Protagenic Therapeutics Stock (NASDAQ:PTIX)Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Read More PTIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTIX Stock News HeadlinesApril 18, 2024 | americanbankingnews.comProtagenic Therapeutics (PTIX) vs. Its Peers Head-To-Head SurveyApril 17, 2024 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston SummitApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 17, 2024 | finance.yahoo.comProtagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston SummitApril 2, 2024 | msn.comProtagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comProtagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric DisordersMarch 25, 2024 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings CallFebruary 13, 2024 | finance.yahoo.comProtagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related DisordersApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.December 17, 2023 | morningstar.comProtagenic Therapeutics Inc PTIXNovember 14, 2023 | seekingalpha.comPTIX Protagenic Therapeutics, Inc.October 13, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Date of Annual Shareholder MeetingOctober 13, 2023 | finance.yahoo.comProtagenic Therapeutics Announces Date of Annual Shareholder MeetingSeptember 26, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114September 26, 2023 | finance.yahoo.comProtagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114June 17, 2023 | uk.finance.yahoo.comPTIX - Protagenic Therapeutics, Inc.March 24, 2023 | benzinga.comProtagenic Therapeutics Stock (NASDAQ:PTIX), DividendsMarch 22, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-4 Reverse Stock SplitMarch 22, 2023 | finance.yahoo.comProtagenic Therapeutics to Effect 1-for-4 Reverse Stock SplitSeptember 7, 2022 | investing.comPTIX_old Historical DataAugust 12, 2022 | finance.yahoo.comProtagenic Therapeutics, Inc. (PTIX)April 26, 2022 | finance.yahoo.comProtagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27thJanuary 20, 2022 | nasdaq.comProtagenic Therapeutics, Inc. Common Stock (PTIX)November 16, 2021 | finance.yahoo.comProtagenic Therapeutics Announces Third Quarter 2021 Results and Business UpdateAugust 30, 2021 | finance.yahoo.comProtagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ETAugust 17, 2021 | finance.yahoo.comProtagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business UpdateJuly 23, 2021 | marketwatch.comProtagenic Therapeutics Updates on Patient Enrollment for PT00114 Trial, Shares LowerSee More Headlines Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2021Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTIX CUSIPN/A CIK1022899 Webwww.protagenic.com Phone212-994-8200Fax603-761-6223EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-101.81% Return on Assets-82.18% Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book1.51Miscellaneous Outstanding Shares4,440,000Free Float2,794,000Market Cap$5.55 million OptionableNot Optionable Beta0.36 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Co-Founder & Executive Chairman of the Board Dr. Alexander Kenneth Arrow C.F.A. (Age 53)M.D., CFO & Secretary Comp: $150kDr. Andrew Slee (Age 74)Chief Operating Officer Dr. Robert Benjamin Stein M.D. (Age 73)Ph.D., Chief Medical Officer & Director Key CompetitorsHoth TherapeuticsNASDAQ:HOTHVaccinexNASDAQ:VCNXFirst Wave BioPharmaNASDAQ:FWBIAvenue TherapeuticsNASDAQ:ATXIXenetic BiosciencesNASDAQ:XBIOView All CompetitorsInsidersAlexander K ArrowBought 8,000 shares on 10/12/2023Total: $6,480.00 ($0.81/share)View All Insider Transactions PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed in 2024? Protagenic Therapeutics' stock was trading at $0.99 on January 1st, 2024. Since then, PTIX shares have increased by 53.5% and is now trading at $1.52. View the best growth stocks for 2024 here. When is Protagenic Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PTIX earnings forecast. How were Protagenic Therapeutics' earnings last quarter? Protagenic Therapeutics, Inc. (NASDAQ:PTIX) issued its earnings results on Tuesday, November, 16th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. How do I buy shares of Protagenic Therapeutics? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTIX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTIMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
